Delisting risk
XTL Biopharmaceuticals (ADR) (XTLB)
Develops psychedelic therapies and active ingredients through Psyga Bio.
$2.58
Pre-market−0.08 (−3.01%)
At close$2.66(+14.66%)
In millions of USD, except per-share figures
| In millions | Q1 FY22Mar 2022 | Q2 FY22Jun 2022 | Q3 FY22Sep 2022 | Q4 FY22Dec 2022 | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −1 |
| 1 | 0 | −1 | −1 | −1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | 0 | 1 | 0 | 1 | 0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Income before tax | 1 | 0 | −1 | −1 | −1 | 0 | 0 | 0 | 0 | −1 | −1 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | 0 | −1 | −1 | −1 | 0 | 0 | 0 | 0 | −1 | −1 | 0 |
| Net income | 1 | 0 | −1 | −1 | −1 | 0 | 0 | 0 | 0 | −1 | −1 | 0 |
| EPS, basic | $5.76 | −$3.20 | −$9.60 | −$8.96 | −$2.72 | −$1.12 | −$0.64 | −$0.80 | $1.44 | −$2.08 | −$1.60 | −$0.64 |
| EPS, diluted | $5.76 | −$3.20 | −$9.60 | −$8.96 | −$2.72 | −$1.12 | −$0.64 | −$0.80 | $1.44 | −$2.08 | −$1.60 | −$0.64 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 1 | 0 | −1 | 0 | −1 | 0 | 0 | 0 | 0 | −1 | 0 | 0 |